ABSTRACT
Background Early neurological deterioration (END) after thrombolysis in acute ischemic stroke (AIS) cannot be ignored. Our aim is to establish an interpretable machine learning (ML) prediction model for clinical practice.
Methods Patients in this study were enrolled from a prospective, multi-center, web-based registry database. Demographic information, treatment information and laboratory tests were collected. END was defined as an increase of ⩾2 points in total National Institutes of Health Stroke Scale (NIHSS) score within 24 hours after thrombolysis. Eight ML models were trained in the training set (70%) and the tuned models were evaluated in the test set (30%) by calculating the area under the curve (AUC), sensitivity, specificity, accuracy, and F1 scores. Calibration curves were plotted and brier scores were calculated. The SHapley Additive exPlanations (SHAP) analysis and web application were developed for interpretation and practice.
Results A total of 1956 patients were included in the analysis. Of these, 305 patients (15.6%) experienced END. We used logistic regression to identify six important variables: hemoglobin, white blood cell count, the ratio of lymphocytes to monocytes (LMR), thrombin time, onset to treatment time, and prothrombin time. In the test set, the results showed that the Extreme gradient boosting (XGB) model (AUC 0.754, accuracy 0.722, sensitivity 0.723, specificity 0.720, F1 score 0.451) exhibited relatively good performance. Calibration curves showed good agreement between the predicted and true probabilities of the XGB (brier score=0.016) model. We further developed a web application based on it by entering the values of the variables (https://ce-bit123-ml-app1-13tuat.streamlit.app/).
Conclusions Through the identification of critical features and ML algorithms, we developed a web application to help clinicians identify high-risk of END after thrombolysis in AIS patients more quickly, easily and accurately as well as making timely clinical decisions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2100045258
Funding Statement
This work was funded by the NHC Key Laboratory of Prevention and treatment of Cerebrovascular Disease, Henan Key Laboratory of Cerebrovascular Diseases?Zhengzhou University?, the Non-profit Central Research Institute and Major Science to Yuming Xu?2020-PT310-01?and Technology Projects of Henan Province in 2020 to Yuming Xu (201300310300).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Tel./fax: +86 13949113087, E-mail address: fccgaoy1{at}zzu.edu.cn;gaoyuanzdy{at}126.com
Tel./fax: +86 17803890996, E-mail address: zongce17803890996{at}126.com;3149597676{at}qq.com
Tel./fax: +86 15738396663, E-mail address: 15738396663{at}163.com
Tel./fax: +86 15836706311, E-mail address: zhangke15836706311{at}163.com
Tel./fax: +86 18790678961, E-mail address: yangredxun{at}163.com
Tel./fax: +86 17603719696, E-mail address: 17603719696{at}163.com
Tel./fax: +86 13673990639, E-mail address: wycyunchao{at}126.com
Tel./fax: +86 18638223817, E-mail address: liyapeng777{at}126.com
Tel./fax: +86 15036131917, E-mail address: lk15036131917{at}163.com
Tel./fax: +86 13633835271, E-mail address: yangjing9527{at}126.com
Tel./fax: +86 18337120001, E-mail address: yushengli1970{at}163.com
Tel./fax: +86 13603983297, E-mail address: fccsongb{at}zzu.edu.cn; songbo76{at}sina.com
Tel./fax: +86 13903711125, E-mail address: xuyuming{at}zzu.edu.cn
Data Availability
Data are available upon reasonable request.
Non-standard Abbreviations and Acronyms
- AIS
- acute ischemic stroke
- END
- early neurological deterioration
- NIHSS
- National Institutes of Health Stroke Scale
- ML
- machine learning
- LMR
- lymphocyte to monocyte ratio
- SHAP
- SHapley Additive exPlanations
- OTT
- onset to treatment time
- DWI
- diffusion weighted imaging
- AUC
- area under the curve
- ROC
- receiver operating characteristic
